(2015) 309:G80715
Gastrointestinal effects represent the most frequently reported adverse reactions, occurring in a substantial proportion of patients, particularly during treatment initiation and dose escalation: Nausea (very common, affecting more than 1 in 10 people) typically peaks during the first few weeks and often diminishes with continued treatment [1] [2] Diarrhoea (very common, affecting more than 1 in 10 people) Vomiting (common, affecting up to 1 in 10 people) Abdominal pain, constipation, and dyspepsia occur with variable frequency Reduced appetite is an expected pharmacological effect contributing to weight loss but may occasionally be excessive These gastrointestinal symptoms usually improve over time as the body adjusts to the medication
C.GlusmanG.LevyR.LaustedC.et al (2017)
Initially derived from Melanotan IIa peptide known for its tanning effectsPT-141 was discovered to have significant potential in enhancing sexual desire, leading to its targeted use for libido enhancement
In other words, Big Pharma isnt protecting actual innovation, but gaming the patent system to block competition, keep prices high, and boost profits
Glaucoma Glaucoma is a leading cause of irreversible blindness characterized by progressive RGC degeneration [97]